← Back to headlines
AbbVie Reports Mixed Q1 Drug Revenues
AbbVie's Q1 revenues showed a 39% decline for Humira, while Skyrizi increased by 31% and Rinvoq by 23% year-over-year.
29 Apr, 12:04 — 29 Apr, 12:04
Sources
Showing 1 of 1 sources
AbbVie's Q1 revenues showed a 39% decline for Humira, while Skyrizi increased by 31% and Rinvoq by 23% year-over-year.